Last reviewed · How we verify
NCT05368805
Fruquintinib DDI Study With P-gp and BCRP Substrates
Completed
Phase 1
Last updated 6 October 2022
What this trial tests
Phase 1 trial testing Fruquintinib in Metastatic Colorectal Cancer in 32 participants. Completed in 22 April 2022.
Timeline
2 March 2022
Primary endpoint
22 April 2022
22 April 2022
22 April 2022
Quick facts
| Lead sponsor | Hutchmed |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 32 |
| Start date | 2 March 2022 |
| Primary completion | 22 April 2022 |
| Estimated completion | 22 April 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Fruquintinib — full drug profile →
- Dabigatran Etexilate (DABIGATRAN) — full drug profile →
- Rosuvastatin (rosuvastatin) — full drug profile →
Conditions studied
- Metastatic Colorectal Cancer — all drugs for Metastatic Colorectal Cancer →
Sponsor
Hutchmed — full company profile →
Who can join
Adults 18 to 55, any sex, with Metastatic Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Fruquintinib DDI Study with P-gp and BCRP Substrates
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Metabolic reprogramming in colorectal cancer: regulatory networks and therapy.
Zhang J, Zou S, Fang L. · · 2023 · cited 42× · PMID 36755301 · DOI 10.1186/s13578-023-00977-w -
Targeting the Hippo Pathway in Gastric Cancer and Other Malignancies in the Digestive System: From Bench to Bedside.
Liu X, Wang Y, Chen B, Chan WN, et al · · 2022 · cited 21× · PMID 36289774 · DOI 10.3390/biomedicines10102512 -
A Phase 1 Study to Assess the Effect of Fruquintinib on the Pharmacokinetics of P-gp and BCRP Substrates in Healthy Subjects.
Gonzalez M, Yang Z, Schelman WR, Zhou X, et al · · 2025 · PMID 41246975 · DOI 10.1111/cts.70408
Verify or expand the search:
- PubMed search for NCT05368805
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fruquintinib
Trials testing the same drug.
- NCT07510932 — Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients · Phase 2 · not yet recruiting
- NCT07502014 — A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruqui · Phase 2 · not yet recruiting
- NCT07124858 — Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metast · NA · not yet recruiting
- NCT07446465 — FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectab · Phase 4 · not yet recruiting
- NCT07235293 — A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorecta · Phase 2 · recruiting
Other recruiting trials for Metastatic Colorectal Cancer
Currently open trials in the same condition.
- NCT07416552 — A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC) · Phase 1 · recruiting
- NCT07314294 — Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients · Phase 2 · recruiting
- NCT06856837 — - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Misma · Phase 2 · recruiting
- NCT06959550 — Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorect · Phase 2 · recruiting
- NCT06808685 — Real World Multicenter National Study to Evaluate the Effectiveness and Safety of Biosimilar Bevacizumab Elovie · recruiting
Other Hutchmed trials
Trials by the same sponsor.
- NCT07409428 — A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL · Phase 3 · recruiting
- NCT07396584 — HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor · Phase 1, PHASE2 · recruiting
- NCT07228247 — A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07348133 — Study of Food Effect on Pharmacokinetics of HMPL-523 Acetate Tablets · Phase 1 · completed
- NCT07331194 — Pharmacokinetics and Bioequivalence Study of HMPL-523 Acetate Tablets in Humans · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT05368805 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hutchmed
- Last refreshed: 6 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05368805.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing